VIOLIN: Vaccine Investigation and Online Information Network

Vaccine Detail

MAGE-A3-genetically modified lymphocytes

Vaccine Information

Vaccine Name: MAGE-A3-genetically modified lymphocytes
Target Pathogen: Cancer
Target Disease: Cancer
Vaccine Ontology ID: VO_0007637
Type: autologous lymphocytes
Status: Clinical trial
Antigen: MAGE-A3(Russo et al., 2013)
Immunization Route: Intramuscular injection (i.m.)

Host Response

Human Response

Vaccine Immune Response Type: VO_0003057
Immune Response: increase of anti-TK and anti-MAGE-A3 T-cells after vaccination, (Russo et al., 2013)

References

Russo et al., 2013: Russo V, Pilla L, Lunghi F, Crocchiolo R, Greco R, Ciceri F, Maggioni D, Fontana R, Mukenge S, Rivoltini L, Rigamonti G, Mercuri SR, Nicoletti R, Maschio AD, Gianolli L, Fazio F, MarchianÃ² A, Florio AD, Maio M, Salomoni M, Gallo-Stampino C, Fiacco MD, Lambiase A, Coulie PG, Patuzzo R, Parmiani G, Traversari C, Bordignon C, Santinami M, Bregni M. Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes. International journal of cancer. Journal international du cancer. 2013; 132(11); 2557-2566. [PubMed: 23151995].